Molina's $9.50 Promise Is Mostly a Bridge, Not a Turn

MOH calls the Medicaid trough and lays out a near-doubling of 2027 EPS, but the core margin recovery is still an assumption.

MOH · Earnings Call · 2026-10-22

The bridge is real — and mostly nonrecurring

Molina Healthcare used its third-quarter call to do something it has not done in several quarters: put a hard number on the other side of the Medicaid trough. Preliminary 2027 EPS building blocks sum to more than $9.50, against 2026 guidance of at least $5.25. The stock has been a value trap for two years—down 48% from its 2024 peak—so the market's question is not whether the 2027 number is bigger, but whether it is durable. Third-quarter adjusted EPS was $0.89 on $10.5 billion of premium revenue, with a 92.9% consolidated MCR and a 0.6% adjusted pre-tax margin. On the surface, that is an 80% EPS increase. Under the hood, it is a cleanup of known drags.

Preliminary EPS building blocks for 2027 sum to more than $9.50 per share. To get there, we begin with full year 2026 guidance of at least $5.25 per share. Add approximately $4 of known embedded earnings realization... then add $0.75, assuming Marketplace reaches at least breakeven next year. Finally, California's termination of the UIS program will be a slight headwind.
Mark Keim, CFO · 2026-10-22

Note what is not in that bridge: any improvement in legacy Medicaid. The 2027 number assumes the core Medicaid MCR is flat at best. The doubling comes from rolling off the Florida startup loss, exiting MAPD, bringing Marketplace to breakeven, and harvesting operating leverage. That is a legitimate bridge—these are real dollars—but it is not evidence of a Medicaid margin recovery. It is evidence that 2026 was burdened by one-time items. The P&L still looks impaired. In the latest filed quarter, total revenue of $10.9 billion, down 5% year over year, came with operating income of $145 million, down 61%, and net income of $60 million. That is why the 2027 bridge matters: without the one-time drags disappearing, the core business is barely profitable. Joe Zubretsky framed the quarter as the start of the turn: “The imbalance between rates and trend appears to have stabilized, which supports our view that current Medicaid margins represent the trough in a multi-year cycle.” — Joe Zubretsky, President and CEO · 2026-10-22 That may prove right, but Molina has been here before. In the prior quarter he called 2026 a trough year for margins while insisting trend had plateaued: “And that's why we say that this is a trough year for margins, while the trend is still high at 5% -- it has plateaued...” — Joseph Zubretsky, President and CEO · 2026-07-23 The difference this time is not the rhetoric; it is the rate data.

Rates are finally leaning the right way

Management now sees 2027 rates around 6% and core trend at 5.5%–6%, including 50 basis points of conservatism. The January 1 cohort—55% of full-year premium—has known draft rates averaging about 7% on 80% of that cohort. That is the first hard evidence that the rate cycle is bending toward Molina rather than away from it. It is also why the 2027 bridge can be credible without assuming any legacy margin improvement: if rates merely match trend, the legacy MCR is flat, and the nonrecurring items do the rest. Mark Keim was explicit: “Assuming we hold rates equal to trend, expect a flat MLR year-over-year.” — Mark Keim, CFO · 2026-10-22 That is the real bar for 2027. Anything better is upside; anything worse breaks the bridge. The setup is helped by the fact that Molina only needs a fraction of what the market needs to recover. Management estimates the Medicaid market is 300 basis points underfunded, while Molina needs about 90 basis points to reach its 2.5% 2029 target. Every 100 basis points of Medicaid MCR is worth roughly $5 per share—which is why the first quarter of 2027 will be watched so closely.

Work requirements: smaller, slower, and already priced?

The other swing factor is the implementation of work requirements and semiannual reverifications, part of the broader policy reforms wave hitting Medicaid. Molina now assumes a 6% membership decline in 2027, with about 1% acuity impact embedded in trend. That is a faster near-term loss than the company outlined a quarter ago. In July, Mark Keim described a three-year, 8%–9% cumulative decline—'2% to 3% a year':

We're expecting over the next 3 years, an 8% to 9% decline, which is why we say 2% to 3% a year.
Mark Keim, CFO · 2026-07-23

The new 6% first-year assumption pulls most of that forward. That sounds bearish for membership, but it may be conservative on acuity. Nebraska, the early adopter, is seeing 90% of renewing members re-enroll and 20% qualify for frailty. Joe Zubretsky said “80% of our states have what I would say are interpretations of the guidance that lean more toward enrollment than disenrollment.” — Joe Zubretsky, President and CEO · 2026-10-22 If that holds, the 6% membership loss is a volume headwind, not a margin shock—especially because the first-year revenue effect is only a half year. The risk is that states tighten later, or that California's lower asset limit removes healthier members. Management says it is modeled bottom-up, but this is still a policy-dependent assumption, not an actuarial certainty.

Florida is the proof point—and the timing risk

The Florida CMS contract is the single largest moving part. Molina took on 115,000 members and a $6 billion annual run rate. In Q4 it expects a 99% MCR and a 5% pre-tax loss; to reach breakeven next year it must find 500 basis points, 200 from one-time reserves and 300 from G&A and MCR. Mark Keim: “I expect about a 99% MCR and a 5% pre-tax loss. To get the 5% pre-tax loss to zero next year, I got to find 500 basis points at least.” — Mark Keim, CFO · 2026-10-22 That is a credible path for a high-acuity program Molina says it knows how to run, but it is still a new program with new networks and new reserving. Georgia and Texas are the offset. The RFP awards have been delayed in court, cutting 2027 premium to at least $45 billion from a prior $46.5 billion and reducing expected embedded-earnings harvest to $4 per share from $4.50. That is not a thesis-breaker; it is a reminder that the RFP pipeline is not entirely in Molina's hands. The Marketplace exit from most states and the MAPD exit are cleaner: both remove drag. In July, guidance included a $0.75 Marketplace loss: “right now, our guidance is a $0.75 loss in Marketplace for the full year.” — Mark Keim, CFO · 2026-07-23 Getting that to breakeven is a large part of the 2027 step-up.

What the tape and balance sheet say

The equity is not pricing perfection. At 0.3x revenue, Molina trades like a business with a broken earnings model, not one about to earn $9.50. The shares are up 8.2% over the last 90 days but still 10.8% below the July peak and 48% below the 2024 high. The balance sheet is serviceable but less of a cushion: liabilities are 73.9% of assets, interest coverage is 2.7x, and free cash flow was negative $350 million in the latest filed quarter. The call was more credible than the headline because management did not put legacy Medicaid improvement into the 2027 number. That is the right way to under-promise. But it also means the 'turn' is not yet in guidance; it is in the upside case. For a stock at 0.3x revenue, a credible bridge to $9.50 may be enough to change the conversation. For a re-rating, Molina needs the first quarter of 2027 to show the legacy MCR actually flat-to-better—not just the absence of one-time drags. The watch items are simple: January 1 rate notices, the Q4 Florida MCR, and whether work-requirement disenrollments stay as gentle as Nebraska's early read.